8-K: OrthoPediatrics Q2 Revenue Soars, Boosts 2025 Outlook

OrthoPediatrics Corp. reported record second-quarter 2025 revenue of $61.1 million, a 16% increase year-over-year, and raised its full-year 2025 revenue guidance.

Summary

• Achieved a new record high total revenue of $61.1 million for the second quarter of 2025, marking a 16% increase from $52.8 million in Q2 2024.
• Domestic revenue grew by 17% and international revenue increased by 12% during the quarter.
• Worldwide Trauma & Deformity revenue increased by 10%, and worldwide Scoliosis revenue surged by 35% compared to Q2 2024.
• Adjusted EBITDA rose by 58% to $4.1 million in Q2 2025, up from $2.6 million in Q2 2024.
• Reported a GAAP diluted loss per share of ($0.30) in Q2 2025, compared to ($0.26) in Q2 2024.
• Improved non-GAAP diluted loss per share to ($0.11) in Q2 2025, from ($0.23) in Q2 2024.
• Expanded the OrthoPediatrics Specialty Bracing Division (OPSB) with new clinics and entry into two new territories, including its first international operation in Ireland.
• Increased full-year 2025 revenue guidance to a range of $237.0 million to $242.0 million, up from the previous range of $236.0 million to $242.0 million, representing 16% to 18% growth over 2024.

Sentiment

Score: 7

Explanation: The sentiment is largely positive due to record revenue, strong growth across key segments, significant Adjusted EBITDA improvement, and increased full-year guidance. The expansion of the OPSB division and the outlook for positive free cash flow are also strong positives. However, the widening GAAP net loss and a decrease in gross profit margin temper the overall sentiment slightly, preventing a 'strong buy' score.

Positives

• Record high total revenue of $61.1 million in Q2 2025, a 16% increase year-over-year.
• Strong growth in key segments: domestic revenue up 17%, international revenue up 12%, Scoliosis revenue up 35%, and Trauma & Deformity revenue up 10%.
• Adjusted EBITDA increased significantly by 58% to $4.1 million in Q2 2025.
• Improved non-GAAP diluted loss per share to ($0.11) from ($0.23) year-over-year.
• Successful expansion of the OrthoPediatrics Specialty Bracing Division (OPSB) into new clinics and territories, including Ireland.
• Increased full-year 2025 revenue guidance, reflecting confidence in continued growth.
• On track to achieve adjusted EBITDA targets and generate positive free cash flow by the fourth quarter of 2025, aiming for full-year free cash flow breakeven in 2026.
• Cash, cash equivalents, short-term investments and restricted cash increased to $72.2 million as of June 30, 2025, from $70.8 million as of December 31, 2024.

Negatives

• GAAP diluted loss per share widened to ($0.30) in Q2 2025, compared to ($0.26) in Q2 2024.
• Gross profit margin decreased to 72% in Q2 2025, down from 77% in Q2 2024, primarily due to higher 7D growth and international Scoliosis set sales which generate lower margins.
• Total operating expenses increased by 18% to $54.7 million in Q2 2025, driven by restructuring charges, increased non-cash stock compensation, and personnel additions for growth.
• Net loss for the second quarter of 2025 widened to $7.1 million, compared to $6.0 million for the same period last year.
• Sports Medicine/Other revenue decreased by 33% to $0.9 million in Q2 2025, compared to $1.3 million in Q2 2024.

Risks

• Risks related to widespread health emergencies, such as COVID-19 and respiratory syncytial virus, and their potential impact on product demand and the company's ability to respond to related challenges.
• General risks, uncertainties, and factors outlined in the company's Annual Report on Form 10-K filed with the SEC on March 5, 2025, and subsequent SEC reports.

Future Outlook

The company increased its full-year 2025 revenue guidance to a range of $237.0 million to $242.0 million, representing 16% to 18% growth over 2024. It reiterated its annual set deployment guidance at $15.0 million and adjusted EBITDA guidance at $15.0 million to $17.0 million for the full year 2025. Management expects to achieve adjusted EBITDA targets and generate positive free cash flow by the fourth quarter of 2025, setting the stage for full-year free cash flow breakeven in 2026.

Management Comments

• "We delivered another solid quarter achieving 16% global revenue growth fueled by strong procedure and clinic volumes, and continued market share gains across all key business segments, including standout performance in Scoliosis, Trauma, 7D Enabling Technologies, and our rapidly expanding OPSB franchise."
• "With growing momentum across our core businesses, new product adoption, and continued aggressive expansion of OPSB, we remain confident in our outlook for the remainder of 2025 and beyond."
• "We are on track to achieve our adjusted EBITDA targets, and generate positive free cash flow by the fourth quarter of 2025 setting the stage for full-year free cash flow breakeven in 2026."

Industry Context

OrthoPediatrics Corp. operates exclusively in the pediatric orthopedics market, offering a comprehensive product portfolio of 82 systems across trauma and deformity, scoliosis, and sports medicine/other procedures. The company's global sales organization distributes products in the United States and over 75 other countries. The expansion of its OrthoPediatrics Specialty Bracing Division (OPSB) into new territories, including its first international operation in Ireland, indicates a strategic focus on broadening its market reach and product offerings within its specialized niche.

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, increased guidance, and improved Adjusted EBITDA, indicating a healthy business trajectory.
• Employees: Potential negative impact due to staffing reductions as part of the global restructuring plan.
• Customers/Patients: Positive impact as the company helped over 37,000 children in Q2 2025 and continues to expand its product offerings and service reach through the OPSB division.

Next Steps

• Host a conference call on August 5, 2025, at 4:30 p.m. ET to discuss the results.
• Generate positive free cash flow by the fourth quarter of 2025.
• Achieve full-year free cash flow breakeven in 2026.

Key Dates

Recommendation

The company demonstrates robust operational performance with record revenue, strong growth in core segments, and a significant increase in Adjusted EBITDA. The raised full-year revenue guidance and the clear path to positive free cash flow by Q4 2025 and breakeven in 2026 signal strong future financial health and operational efficiency improvements. While the GAAP net loss widened and gross margin slightly declined, the underlying business momentum and strategic expansions outweigh these concerns for a growth-oriented investor.

Keywords

pediatric orthopedics, medical devices, orthopedics, scoliosis, trauma, deformity, bracing, healthcare, KIDS